¡Advertencia! El contenido en esta página está disponible solo en los siguientes idiomas: Inglés

The company employs over 500 people and is led by President & Managing Director Simone Volpi.

In FY 2025, Comecer achieved an annual turnover of approximately €139 million. Around 55% of its sales come from the radiopharmaceutical equipment market, where the company’s specialized shielding systems support the production, handling, and distribution of radiopharmaceuticals used in the diagnosis and treatment of diseases such as cancer and cardiovascular disorders. The remaining share derives from aseptic processing equipment, pharmaceutical packaging solutions, isolators, and incubators for Advanced Therapy Medicinal Products (ATMP) and regenerative cell therapies.

Supporting these highly specialized applications requires the highest levels of engineering reliability and process control. For this reason, rigorous engineering, fabrication, and verification processes are applied throughout the lifecycle of Comecer systems, reflecting the company’s commitment to reliability, safety, and regulatory excellence in GMP manufacturing environments.

Cancel

Technical

Chiudi

Cancel

Statistical

Chiudi

Cancel

Targeting

Chiudi